MindMed Highlights Phase 3 Progress and Billion-Dollar Potential in Anxiety and Depression Therapies

Reuters01-12

MindMed Highlights Phase 3 Progress and Billion-Dollar Potential in Anxiety and Depression Therapies

Mind Medicine (MindMed) Inc. has highlighted progress across its therapeutic pipeline, with three Phase 3 clinical trial readouts anticipated in 2026 for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company emphasizes the significant unmet need in psychiatry due to limited and recycled treatment options for anxiety and depressive disorders, which affect over 50 million people and are growing at an annual rate of over 5%. Recent Phase 2b studies demonstrated a statistically significant dose response, supporting 100 µg as the optimal dose for further development. The findings suggest the results are robust and unlikely to be explained by functional unblinding. MindMed is advancing multiple product candidates, including lysergide tartrate for MDD and DT4022 (R(-)-MDMA) for autism spectrum disorder, through various stages of clinical development. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602351196?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602351196","market":"us","top_or_hot":-1,"title":"MindMed Highlights Phase 3 Progress and Billion-Dollar Potential in Anxiety and Depression Therapies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Highlights Phase 3 Progress and Billion-Dollar Potential in Anxiety and Depression Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has highlighted progress across its therapeutic pipeline, with three Phase 3 clinical trial readouts anticipated in 2026 for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company emphasizes the significant unmet need in psychiatry due to limited and recycled treatment options for anxiety and depressive disorders, which affect over 50 million people and are growing at an annual rate of over 5%. Recent Phase 2b studies demonstrated a statistically significant dose response, supporting 100 µg as the optimal dose for further development. The findings suggest the results are robust and unlikely to be explained by functional unblinding. MindMed is advancing multiple product candidates, including lysergide tartrate for MDD and DT4022 (R(-)-MDMA) for autism spectrum disorder, through various stages of clinical development. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindMed Highlights Phase 3 Progress and Billion-Dollar Potential in Anxiety and Depression Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindMed Highlights Phase 3 Progress and Billion-Dollar Potential in Anxiety and Depression Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 19:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Highlights Phase 3 Progress and Billion-Dollar Potential in Anxiety and Depression Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has highlighted progress across its therapeutic pipeline, with three Phase 3 clinical trial readouts anticipated in 2026 for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company emphasizes the significant unmet need in psychiatry due to limited and recycled treatment options for anxiety and depressive disorders, which affect over 50 million people and are growing at an annual rate of over 5%. Recent Phase 2b studies demonstrated a statistically significant dose response, supporting 100 µg as the optimal dose for further development. The findings suggest the results are robust and unlikely to be explained by functional unblinding. MindMed is advancing multiple product candidates, including lysergide tartrate for MDD and DT4022 (R(-)-MDMA) for autism spectrum disorder, through various stages of clinical development. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4547","symbol_name":"WSB热门概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7hzFnH:1","article_id":"2602351196","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602351196","pubTimestamp":1768218118,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mind Medicine  Inc. has highlighted progress across its therapeutic pipeline, with three Phase 3 clinical trial readouts anticipated in 2026 for the treatment of generalized anxiety disorder  and major depressive disorder . The company emphasizes the significant unmet need in psychiatry due to limited and recycled treatment options for anxiety and depressive disorders, which affect over 50 million people and are growing at an annual rate of over 5%. Recent Phase 2b studies demonstrated a statistically significant dose response, supporting 100 g as the optimal dose for further development. The findings suggest the results are robust and unlikely to be explained by functional unblinding. MindMed is advancing multiple product candidates, including lysergide tartrate for MDD and DT4022  for autism spectrum disorder, through various stages of clinical development. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4547":"WSB热门概念","DFTX":"Definium Therapeutics","BK4007":"制药"},"translate_title":"MindMed强调了焦虑和抑郁治疗的3期进展和数十亿美元的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":0.9,"DFTX":0.9},"content_text":"MindMed Highlights Phase 3 Progress and Billion-Dollar Potential in Anxiety and Depression Therapies\n    \n\nMind Medicine (MindMed) Inc. has highlighted progress across its therapeutic pipeline, with three Phase 3 clinical trial readouts anticipated in 2026 for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company emphasizes the significant unmet need in psychiatry due to limited and recycled treatment options for anxiety and depressive disorders, which affect over 50 million people and are growing at an annual rate of over 5%. Recent Phase 2b studies demonstrated a statistically significant dose response, supporting 100 µg as the optimal dose for further development. The findings suggest the results are robust and unlikely to be explained by functional unblinding. MindMed is advancing multiple product candidates, including lysergide tartrate for MDD and DT4022 (R(-)-MDMA) for autism spectrum disorder, through various stages of clinical development. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602351196","isCrawlerRequest":true}